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The worldwide burden of sickle cell disease is enormous, with over
200,000 infants born with the disease each year in Africa alone.
Induction of fetal hemoglobin is a validated strategy to improve
symptoms and complications of this disease. The development of
targeted therapies has been limited by the absence of discrete
druggable targets. We developed a unique bead-based strategy for
the identiﬁcation of inducers of fetal hemoglobin transcripts in pri-
mary human erythroid cells. A small-molecule screen of bioactive
compounds identiﬁed remarkable class-associated activity among
histone deacetylase (HDAC) inhibitors. Using a chemical genetic
strategy combining focused libraries of biased chemical probes and
reverse genetics by RNA interference, we have identiﬁedHDAC1 and
HDAC2 as molecular targets mediating fetal hemoglobin induction.
Our ﬁndings suggest the potential of isoform-selective inhibitors of
HDAC1 and HDAC2 for the treatment of sickle cell disease.
histone | acetylation | hemoglobinopathies | chromatin
Sickle cell disease results in the loss of millions of disability-adjusted life-years annually (1). The disorder is attributable
to homozygous inheritance of a single amino acid substitution in
the β-globin gene that leads to polymerization of deoxygenated
hemoglobin, deformation of red blood cells, microvascular oc-
clusion, hemolysis, and consequent disease manifestations, in-
cluding pain, strokes, and pulmonary complications (2). Abun-
dant biochemical, epidemiological, and clinical evidence have
shown that a high level of γ globin, the fetal form of β globin,
inhibits the aberrant polymerization of sickle hemoglobin and
ameliorates the disease phenotype (2). The only Food and Drug
Administration (FDA)-approved drug for sickle cell disease, hy-
droxyurea, causes signiﬁcant induction of fetal hemoglobin, de-
creased disease severity, and beneﬁts overall mortality (3–6). Nev-
ertheless, hydroxyurea has bone marrow-suppressive effects and
is ineffective in a signiﬁcant portion of patients (5–7). A drug that
induces fetal hemoglobin more substantially with less myelosup-
pression would be expected to have greater therapeutic utility in
sickle cell disease.
Transcriptional regulation of the human globin gene locus has
been investigated intensively. Gamma-globin gene expression is
inﬂuenced by transcription factors (GATA-1, EKLF, NF-E4p22,
Ikaros) and chromatin modifying enzymes [SWI/SNF complex,
HATs, and histone deacetylase (HDACs)] as part of multiprotein
complexes, and a unique, dynamic chromatin structure termed the
β-globin active chromatin hub (βACH) (8–11). Polymorphisms in
BCL11A, a transcriptional repressor, alter baseline fetal hemo-
globin levels, and a multiprotein complex containing BCL11a
binds to the β-globin locus, resulting in repression of γ-globin
expression (12–16). Despite this granularity, discrete targets
amenable to ligand discovery efforts have not been identiﬁed and
functionally validated.
Results
Development of a Miniaturized Assay for Globin Switching in Human
Hematopoietic Precursor Cells. An obstacle limiting the develop-
ment of novel inducers of fetal hemoglobin has been the need for
an effective, miniaturized assay capable of supporting high-
throughput screening and lead optimization. We therefore de-
veloped a physiologically-relevant, high-throughput system that
detects the endogenous expression of seven globin mRNA tran-
scripts in primary human erythroid cells using a ﬂuorescent
microspheres detection system (Fig. 1 A and B) (17). In contrast
to reporter-assay systems expressed in cell lines, this assay de-
tects expression of the globin genes within their native chromatin
structure in the therapeutically relevant cell type.
The assay was validated by measuring expression of the globin
genes during erythroid differentiation and in response to known
experimental inducers of fetal hemoglobin. We observed the
expected coordinate induction of globin gene expression during
erythroid differentiation, with higher levels of γ-globin in umbil-
ical cord blood cells compared with adult bone marrow (Fig. 1C).
Four well-studied activators of fetal hemoglobin (hydroxyurea,
valproic acid, sodium butyrate, and 5-azacytidine), increased the
γ/β-globin ratio in a dose-dependent fashion (Fig. 1D) (3, 18–20).
These experiments demonstrate that our assay detects relevant
changes in globin gene expression.
With an assay in hand, we next performed a small-molecule
screen (see Table S1 for details) with particular emphasis on
bioactive and FDA-approved compounds that could be most
rapidly translated for clinical investigation. Using the γ/β-globin
ratio as the primary screening measurement, previously reported
inducers of fetal hemoglobin (including hemin, zileuton, rapa-
mycin, chromomycin, mithramycin, and cisplatin) increased the
γ/β ratio modestly or only at doses that substantially decreased
cell viability (Fig. S1) (8, 20). The corticosteroid triamcinolone
also scored highly in the assay (Fig. S1G), consistent with the
known effect of corticosteroids in inducing γ-globin (21). Be-
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cause of the toxicity associated with chronic corticosteroid use,
however, this ﬁnding was not pursued further.
Among the highest-scoring compounds were multiple, distinct
HDAC inhibitors. Secondary screening of assay positives in the
primary globin induction assay identiﬁed dose-response behavior
for all compounds, including natural products and simple, com-
mercial hydroxamic acids (Fig. S2). The varied structural classes
and diversity in zinc-binding features observed in this set suggest
a common, on-target mechanism of action. HDAC inhibition has
previously been established as a route to fetal hemoglobin in-
duction. Indeed, the observed induction of γ-globin in human
subjects treated with sodium butyrate and sodium valproate has
been linked to weak HDAC inhibitory activity (22–25). Despite
extensive research in this area, the speciﬁc targets among the 18
known human enzymes are not known, in part because of the
perceived nonselective action of investigational and tool com-
pounds. We therefore employed a chemical genetic strategy to
identify the HDAC enzymes minimally necessary for γ-globin
gene repression.
HDAC Inhibitors Induce Fetal Hemoglobin and Modulate Chromatin
Structure. First, we studied an expanded collection of commercial,
investigational, and novel HDAC inhibitors. Notably, within this
collection were 600 compounds curated from a 7,200-member
diversity-oriented synthesis library of 1,3-dioxanes biased for pu-
tative HDAC inhibition by one of three metal chelating features:
an o-aminoanilide, carboxylic acid, or hydroxamic acid (26).
Molecules were selected for study based on a prior demonstration
of histone deacetylase inhibitory activity in a cell-based assay (26).
Small molecules demonstrating the most robust γ/β-globin induc-
tion were resynthesized or purchased, as required. Several com-
pounds from this collection were selected for further, detailed
study because of potent effects on globin gene induction at con-
centrations permissive to cell growth and viability (Fig. S2C).
To quantify more accurately the magnitude of gene regulation,
we examined the effects of compounds on globin gene expression
by quantitative RT-PCR. We found that HDAC inhibitors, in-
cluding NK57, increase the γ/β-globin ratio by up to 10-fold (Fig.
2A). HPLC and ﬂow cytometric analysis of primary human ery-
throid cells using a fetal hemoglobin-speciﬁc antibody demon-
strated an increase in both fetal hemoglobin and the percentage of
F cells, a population of erythroid cells with particularly elevated
levels of fetal hemoglobin, in response to HDAC inhibition (Fig.
2 B and C and Fig. S3). In addition, the ε/β-globin ratio increased
by more than 300-fold with scriptaid, and by 20- to 40-fold with
other compounds (Fig. 2D), although the absolute level of ε-globin
expression remained low (Fig. S4). Given the regulation of
ε-globin, we hypothesized that HDAC inhibitionmight also induce
expression of ζ-globin, the embryonic form of α-globin. We found
that ζ-globin was indeed induced by HDAC inhibitors by as much
as 5- to 10-fold (Fig. 2E). These experiments demonstrate that
HDAC inhibition reverses the ontogeny of globin gene expression
at the adult, fetal, and embryonic globin genes, at both the α- and
β-globin loci, suggesting a central and reversible role of globin locus
histone deacetylation in the developmental silencing of globin genes.
To ascertain a possible mechanism by which HDAC inhibitors
may increase expression of the globin locus, we examined their
effect on the βACH, in which the regulatory sequences from the
β-globin locus control region (LCR) are brought in proximity to
promoters of individual globin genes (8). We employed chro-
mosome conformation capture (3C) to monitor the chromatin
structure of this locus in response to compound treatment with
two high-scoring HDAC inhibitors, SAHA and NK57 (27). Both
compounds induced a conformational change characterized by
increased contact between the LCR and the γ- and ε-globin
promoters, similar to the chromatin state observed in erythroid
cells from umbilical cord blood (Fig. 2F and Fig. S5). Impor-
tantly, the compounds did not alter LCR interactions with other
regions of the β-globin locus. These results are unique in pro-
viding direct evidence for chemical modulation of the structure
of the β-globin locus.
HDAC1 and HDAC2 Repress γ-Globin Gene Expression. The experi-
ments described above all point to small-molecule HDAC inhib-
itors as a potential route to fetal hemoglobin induction for sickle
cell disease. However, all clinically-used HDAC inhibitors are
perceived to be relatively nonspeciﬁc, acting to inhibit multiple
class I and II deacetylases (28). It is then conceivable that combi-
natorial inhibition of HDACs is required for fetal hemoglobin in-
duction. Alternatively, the inhibition of individual HDACs might
account for the effect. To resolve this uncertainty, we ﬁrst corre-
lated the fetal hemoglobin inducing effects of 14 structurally di-
verse HDAC inhibitors (Fig. S6) with their biochemical HDAC
inhibitory activity, using in vitro assays for each of nine deacetylases
(HDAC1-9). Hierarchical clustering of these data pointed to
a strong correlation between γ-globin induction and biochemical
inhibition of HDAC1, HDAC2, and HDAC3, but not the other
HDACs (Fig. 3A). Highlighting this observation, a cluster of in-
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Fig. 1. A unique multiplexed globin screening assay. (A) A multiplexed assay
was designed to detect expression of each globin gene. The β-globin locus
contains embryonic (ε), fetal (γ), and adult (δ and β) globin genes on Chromo-
some (Chr) 11. The α-globin locus is comprisedof embryonic (ζ) andadult (α and
θ) globin genes. (B) Primary human erythroid progenitor cells were generated
from in vitro differentiation of CD34+ bone-marrow cells for 7 d. Cells were
treated with compounds for 3 d, and poly(A) mRNA was puriﬁed on oligo-dT
coated plates and reverse transcribed. Following ligation-mediated ampliﬁca-
tion of globin cDNAs, the bar-coded amplicons were detected by ﬂuorescent
microspheres linked to capture probes complementary to the bar codes. (C)
Expressionofα- andβ-globin increasedduring invitroerythroiddifferentiation.
The expression of γ-globin was higher in cells from umbilical cord blood than
adult bone marrow. Mean ﬂuorescence intensity for each globin gene was
normalized to GAPDH expression. (D) Known small molecules induce the rel-
ative expression of γ-globin relative to β-globin in dose-ranging studies. The
γ/β-globin ratio is shown in red, and the ε/β-globin ratio is shown in black.
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vestigational benzamides (CI-994, MGCD0103, and MS-275)
powerfully activate γ-globin expression but inhibit only HDAC1-3
without observable effects on HDAC4-9 (Fig. 3 B and C and Table
S2). In contrast, the HDAC6-selective tool compound tubacin
failed to elicit marked induction of γ- and ε-globin at high experi-
mental concentrations (Fig. S2C). These experiments suggest that
inhibition ofHDAC1-3, either alone or in combination, is sufﬁcient
to regulate the globin locus.
To further dissect the role of HDAC1-3 in regulating globin
gene expression, we turned to a genetic perturbation strategy.
Primary erythroid cells were infected with lentiviruses harboring
short hairpin RNAs (shRNAs) targeting individual HDAC
transcripts. Knockdown of HDAC1-3 by directed shRNAs was
ﬁrst validated at the RNA and protein levels (Fig. S7). Multiple
effective shRNAs targeting HDAC1 and HDAC2 increased the
relative expression of γ- and ε-globin, but shRNAs targeting
HDAC3 had no effect (Fig. 3 D and E). These experiments
functionally validate HDAC1 and HDAC2 as requisite cor-
epressors for full repression of fetal and embryonic globin ex-
pression observed in adult erythroid cells.
Selectivity of HDAC1 or HDAC2 for Fetal Hemoglobin Induction. Cur-
rent clinical and investigational HDAC inhibitors are limited
in their broad utility by class-associated side effects, such as fa-
tigue, malaise, thrombocytopenia, and cardiotoxicity. Whereas
pharmaceutical HDAC inhibitors (SAHA and LBH-589) exhi-
bited a dose-dependent induction of bulk chromatin acetylation,
selective knock-down of HDAC1 or HDAC2 failed to elicit pat-
terns of nuclear hyper-acetylation, potentially indicating at least
partial redudancy of these factors in global histone acetylation
(Fig. 4A). Notably, all perturbations induced fetal hemoglobin to
comparable levels.
These data establish regulation of the globin locus by HDAC1
and HDAC2, irrespective of global hyperacetylation, a pharma-
codynamic feature associated with cytotoxicity of HDAC inhib-
itors. To extend these speciﬁcity studies and further explore the
transcriptional networks regulated by HDAC1 and HDAC2, we
performed global gene-expression proﬁling. Using three distinct
HDAC1 shRNAs and threeHDAC2 shRNAs tominimize the off-
target effects of individual shRNAs, we identiﬁed both distinct
and overlapping effects of HDAC1 and HDAC2 knockdown. We
deﬁned three gene sets: genes responsive to HDAC1 shRNAs
only, genes responsive by HDAC2 shRNAs only, and genes
modulated by either HDAC1 or HDAC2 shRNAs (Fig. 4B).
Using gene-set enrichment analysis, we conﬁrmed that NK57, an
HDAC inhibitor with high potency (IC50 30 nM) for HDAC1-3
(Table S2), powerfully activated all three gene sets (Fig. 4B). The
HDAC1- and HDAC2-responsive genes comprise a minority of
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Fig. 2. HDAC inhibitors induce γ and ε
hemoglobin in adult progenitors and
exert long-rangeconformational effects
on chromatin. (A) Known and novel
HDAC inhibitors increase the relative ex-
pression of γ-globin RNA, as assayed
by quantitative RT-PCR. Fold induction
was calculated as the γ/β-globin ratio in
compound-treated cells relative to un-
treated cells using theΔΔCtmethod. To
validate changes in globin protein ex-
pression,erythroidprogenitor cellswere
treated with 0.5 mM butyrate, 2 μM
NK57,0.5μMSAHA,1μMNK125,0.5μM
scriptaid. The ratio of γ/β-globin protein
was assayed by HPLC (B), and F-cell per-
centage was assayed by ﬂow cytometry
(C). HPLC traces are shown in Fig. S3. The
HDAC inhibitors also induce the expres-
sion of ε- and ζ-globin gene expression
(D and E), as assayed by quantitative RT-
PCR. (F) NK57 and SAHA alter the chro-
matin structure of the β-globin locus,
increasing contact between the LCR
and the ε- and γ-globin promoters using
3C. Quantitative PCR was performed
usingoneprimer in the LCR (HS5) paired
with primers located throughout the
β-globin locus (Fig. S5). Hypersensitive
sites 1 to 5 in the LCR and the β-globin
locus genes are noted in the schema
at the top. The signal-to-noise ratio
of umbilical cord blood or compound-
treated cells was calculated relative to
untreated bone-marrow cells. Peaks at
the ε- and γ-globin promoters indicate
increased contact with the LCR.
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the gene expression consequences of NK57 or SAHA treatment
(Fig. 4C), indicating that selective inhibition of HDAC1 or
HDAC2 would be expected to activate fetal hemoglobin with
a markedly reduced effect on global gene expression.
Induction of Fetal Hemoglobin in Human Subjects with LBH-589. De-
spite the compelling activity of HDAC inhibitors in cell-culture
systems, it is possible that HDAC inhibitors could fail to induce
fetal hemoglobin expression when tested in vivo, because of
pharmacologic considerations. To address this issue, we ﬁrst
proﬁled two well-established, pharmacologic inducers of γ-globin
for inhibitory potency against the panel of biochemically-active
human histone deacetylases (HDAC1-9), using the optimized
HDAC assay platform. Although markedly less potent than
current pharmaceutical agents, sodium butyrate and valproate
demonstrate a clear preference for class I enzymes (HDAC1,
HDAC2, HDAC3, and HDAC8) and dose-dependent inhibition
of HDAC1 and HDAC2 well within pharmacologically-achiev-
able concentrations (Fig. 5 A and B).
The characterization of these agents as HDAC inhibitors was
discerned decades after the phenotypic identiﬁcation of these
compounds as clinically active substances. Modern HDAC inhib-
itors have emerged through biomarker-directed drug development
using biochemical assays to drive the potency of clinical candi-
dates. Exemplifying these principles is LBH-589 (panobinostat;
Novartis Pharmaceuticals) (29). In comparative biochemical
studies, we observe greater than 1,000-fold increase in potency for
HDAC1 (IC50 0.5 nM) and HDAC2 (IC50 2 nM) compared with
either sodium butyrate or valproate (Fig. 5B and Table S2).
We explored the effect of HDAC1 and HDAC2 inhibition on
fetal hemoglobin production in three adult patients with Hodgkin
lymphoma treated with LBH-589 in the context of a prospective
clinical trial. Serial hemoglobin electrophoresis before and after
treatment indicated that fetal hemoglobin increased by approxi-
mately 2-fold in all patients examined over 3 mo of therapy (Fig.
5C). Notably, this magnitude of fetal hemoglobin induction has
previously been associated with amelioration of symptoms and
complications of sickle cell disease (5).
Discussion
Taken together, our results demonstrate that HDAC1 and
HDAC2 are highly attractive therapeutic targets for sickle cell
disease, establishing a compelling rationale for the further chem-
ical optimization and preclinical development of isoform-selective
A B
C
D E
Fig. 3. A chemical genetic approach to HDAC selectivity for γ globin gene induction. (A) The ability of 14 compounds to inhibit the activity of HDAC1-9 was
tested using in vitro homogeneous assays of deacetylase activity (30). For each compound, the IC50 was calculated for HDAC1-9 (Table S2). The data are
summarized in a heat map in which the colors range from deepest blue (lowest IC50) to red (highest IC50). Effects on globin gene expression for each
compound, at each concentration, are shown in Fig. S6. (B) HDAC biochemical proﬁling data presented for ortho-amino anilides CI-994, MGCD-0103, and MS-
275. (C) Dose-dependent induction of γ-globin transcription by CI-994, MGCD-0103, and MS-275. Doses, in micromolars, are shown on the x axis. The
γ/β-globin ratio is shown in red, at each compound concentration. Error bars represent the mean ± SE of three measurements. (D) Lentiviruses expressing
shRNAs targeting HDAC1 or HDAC2 increased the expression of γ-globin relative to β-globin in primary human erythroid progenitor cells, assayed by
quantitative RT-PCR, and calculated relative to a control shRNA; shRNAs targeting HDAC3 had no effect. The knockdown efﬁciency for each shRNA is shown
in Table S3. (E) HDAC1 and HDAC2 shRNAs also increased the ε/β-globin ratio.
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small molecule HDAC1 and HDAC2 inhibitors. Small molecules
that inhibit these HDAC isoforms, and shRNAs that decrease
expression of their genes, powerfully induce the expression of γ-
and ε-globin. Moreover, we found that selective knockdown of an
individual HDAC is capable of inducing fetal hemoglobin without
alterations in global histone acetylation, with less extensive effects
on global gene expression, and without inhibiting the cell cycle.
Recent human genetic studies support a role for HDAC1 and
HDAC2 as regulators of the globin locus. A genome-wide as-
sociation study searching for regulators of fetal hemoglobin
identiﬁed BCL11A as a candidate (12, 13, 15), and a follow-up
study of BCL11A observed direct interaction with HDAC1 and
HDAC2 by coimmunoprecipitation (14). Genetic ablation of
BCL11A increases the expression of γ-globin in vitro and in vivo
(14, 16). The convergence of our chemical genetic approach with
human genetics studies heightens the candidacy of HDAC1 and
HDAC2 for future drug development efforts.
The molecular basis of sickle cell disease is well understood, yet
drug development has been limited by the absence of speciﬁc
therapeutic targets. Using a strategy which integrates forward
chemical genetics, enzymology, and systematic reverse genetics by
RNA interference, we have identiﬁed a corepressor function for
HDAC1 and HDAC2 in the regulation of the γ- and ε-globin loci.
We demonstrate functionally that high potency inhibitors of these
targets up-regulate fetal hemoglobin in vitro and in human sub-
jects. The development of small molecules speciﬁc to HDAC1 or
HDAC2 has the potential to generate an increasingly effective,
well-tolerated therapy for sickle cell disease. More immediately,
HDAC inhibitors that are currently in clinical trials for other
diseases represent promising candidates for immediate clinical
development, alone or in combination with hydroxyurea.
Methods
Culture of Primary CD34+ Cells. Cryopreserved human bonemarrowCD34+ cells
were obtained from Cambrex (Poietics, Cambrex). Umbilical cord blood was
harvested at Brigham and Women’s Hospital under an institutional review
board-approved protocol. Erythroid differentiation was induced in vitro in
two steps. For the ﬁrst 7 d, cells were cultured in serum-free expansion me-
dium (Stem Cell Technologies) supplemented with 100 U/mL penicillin/strep-
tomycin, 2 mM glutamine, 100 ng/mL stem cell factor, 10 ng/mL interleukin-3,
40 μg/mL lipids, and 0.5 IU/mL erythropoietin (Epo). After 7 d, cells were
cultured in the same medium supplemented with 3 IU/mL Epo.
RNA capture, reverse transcription, and LMA were performed as described
previously (17, 31). See SI Methods for details.
Viability. As an assessment of cytotoxicity, samples from screens were ana-
lyzed with the CellTiter-Glo bioluminescent assay (Promega).
Western Blots. Western blots were performed as described previously. Anti-
bodies against HDAC1, HDAC2, HDAC3, and β-actin were purchased from
Santa Cruz Biotechnology.
F-Cell Quantitation. For F-cell assays, 2 to 4 × 105 cells were harvested and
ﬁxed with 0.05% glutaraldehyde for 10 min at room temperature. Cells were
washed and labeled with an anti-HbF monoclonal antibody (Caltag Labora-
tories). For each sample, 50,000 events were detected using a FACScan ﬂow
cytometer (Becton Dickenson).
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Fig. 4. HDAC1 and HDAC2 regulate unique and overlapping
sets of genes in human erythroid progenitor cells. (A) Primary
human erythroid cells expressing shRNAs targeting HDAC1 or
HDAC2 did not increase total nuclear histone acetylation in
a quantitative, cell-based, immunoﬂuorescence assay, but
treatment with SAHA or LBH-589 did increase nuclear his-
tone acetylation. The shRNAs and compounds induced
γ-globin equivalently in this experiment (data not shown). (B)
Gene expression proﬁling was performed on primary human
erythroid progenitor cells expressing a control shRNA (lucif-
erase, n = 3), three different HDAC1 shRNAs (n = 2 per
shRNA), and three different HDAC2 shRNAs (n = 2 per
shRNA). The heat map shows the top 20 genes that discrim-
inate between treatment condition and control. Genes with
high expression are portrayed in red, and genes with low
expression are shown in blue. (C) Pie chart illustrating the
proportion of genes that are targets of HDAC1, HDAC2, or
both, among all genes regulated by compound treatment
(greater than 1.5-fold).
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Fig. 5. A potent, orally-bioavailable inhibitor of HDAC1 and HDAC2 induces
fetal hemoglobin in human subjects. (A) Inhibition of HDAC1 (red) and
HDAC2 (blue) by sodium butyrate, valproate, and LBH-589. (B) Biochemical
proﬁling data (IC50) of known carboxylic acid inducers of fetal hemoglobin
against HDAC1-9. (C) Correlative biomarker data collected from a pro-
spective, open-label study of oral LBH-589 in hematologic malignancies.
Relative fetal hemoglobin content (circles; HbF; %) was measured by hemo-
globin electrophoresis and total hemoglobin (squares; Hgb; g/dL) was mea-
sured as cyanide-reacted cyanmethemoglobin by absorbance (540 nm) in the
clinical laboratory at the Dana-Farber Cancer Institute. Size of circles and
squares corresponds to dose of LBH-589 (60, 40, or 30 mg; each three times
weekly). Open circles and squares indicate weeks in which doses were held.
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Chromatographic Separation of Hemoglobin Chains. Erythroid cell hemolysates
were prepared as described previously (32). Chromatographic separation of
the globin chains was performed on an Agilent 1100 Capillary LC system at
45 °C with a Jupiter 300 Å C4 reversed-phase column 5 μ, 250 × 0.5 mm
(Phenomenex), using Buffer A: 0.108% TFA, and Buffer B: 80% acetonitrile/
0.07% TFA at 9 μL/min over 140 min. Cell lysates were acidiﬁed with 0.1%
TFA before reverse-phase chromatography.
The 3C was performed as described (33). A control PCR template was
generated by EcoRI digestion and random ligation of a series of BAC clones
covering the β-globin region, as well as a region on chromosome 16 [as
described in Dostie et al. (34)]. See SI Methods for details.
Biochemical Proﬁling of HDACs. The inhibition of HDAC proteins (HDAC1-9)
was determined using a homogenous, kinetic assay, as reported previously
(30). Calculation of IC50 is determined by logistic regression (GraphPad
Prizm Software).
Gene-Expression Proﬁling. RNA was puriﬁed from mononuclear cells using
TRIzol (Invitrogen). Linear ampliﬁcation of 20 ng of total RNAwas performed
using the Ovation Biotin RNA Ampliﬁcation and Labeling System (Nugen).
Labeled cRNA was hybridized to Affymetrix HG_U133A oligonucleotide
microarrays. Raw expression values were normalized using robust multiarray
averaging.Markers ofHDAC1orHDAC2knockdownwere identiﬁedusing the
signal-to-noise metric, selecting probe sets with P ≤ 0.1 and greater than 1.5
mean fold-change. The dataset is available at GEO, accession GSE22369.
Real-Time RT-PCR. RNAwas reverse transcribedusingSuperScript II (Invitrogen)
using oligo(dT) primers. TaqMan primers and probes for real time PCR were
obtained from Applied Biosystems. Each quantitative RT-PCR was performed
in triplicate using a Prism 7900 HT instrument (Applied Biosystems). Themean
threshold cycle (Ct) for each assay was used for further calculations. The ex-
pression of γ, ε, and δ globin were normalized to β-globin (ΔCt). The ΔΔCt
value was calculated by normalizing the ΔCt value to a vehicle-treated con-
trol sample.
Statistical Analysis. The signal-to-noisemetric was used to identify marker genes
in microarray experiments and to analyze chromatin conformation capture data.
For gene x, the signal to noise metric, Sx, is calculated as: Sx = (μ0 – μ1)/(σ0 + σ1),
where μ0 and σ0 are the mean and SD for gene x in class 0, and μ1 and σ1 are
the respective values for class 1.
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